SCHEMBL3530390

SCHEMBL3530390

Nc1nccc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 7/20 0.73
RIPK1 Q13546 6/20 0.73
TEK Q02763 4/20 0.73
KDR P35968 13/20 0.66
FLT3 P36888 7/20 0.66
KIT P10721 7/20 0.66
CSF1R P07333 4/20 0.61
FLT4 P35916 4/20 0.61
LCK P06239 3/20 0.61
LYN P07948 3/20 0.61
BLK P51451 3/20 0.61
FYN P06241 2/20 0.61
SRC P12931 2/20 0.61
ABL1 P00519 1/20 0.61
AURKB Q96GD4 3/20 0.58
PDGFRA P16234 3/20 0.58
ROCK2 O75116 2/20 0.58
RET P07949 2/20 0.58
RPS6KB1 P23443 2/20 0.58
EPHA2 P29317 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524617 0.86 TEK (0.75) FLT1RIPK1TEKKDRFLT3
SCHEMBL3531509 0.85 RIPK1 (0.72) FLT1RIPK1TEKKDRFLT3
SCHEMBL3529762 0.85 KDR (0.72) FLT1RIPK1TEKKDRFLT3
SCHEMBL3529664 0.84 KDR (0.57) FLT1RIPK1TEKKDRFLT3
SCHEMBL3531290 0.83 KDR (0.68) FLT1RIPK1TEKKDRFLT3
SCHEMBL3530426 0.82 FLT1 (0.71) FLT1RIPK1TEKKDRFLT3
SCHEMBL3525709 0.82 RIPK1 (0.60) FLT1RIPK1TEKKDRFLT3
SCHEMBL3527005 0.81 KDR (0.77) FLT1RIPK1KDRFLT3KIT
SCHEMBL3534578 0.80 KDR (0.64) FLT1RIPK1TEKKDRFLT3
SCHEMBL421890 0.79 KIT (1.00) FLT1TEKKDRFLT3KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK FLT1 613/4885RIPK1 629/4885TEK 346/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK FLT1 613/4885RIPK1 629/4885TEK 346/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK FLT1 613/4885RIPK1 629/4885TEK 346/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK FLT1 613/4885RIPK1 629/4885TEK 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.